This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum

This study has been completed.
Information provided by (Responsible Party):
Elizabeth L. Hohmann, MD, Massachusetts General Hospital Identifier:
First received: July 31, 2013
Last updated: July 15, 2016
Last verified: July 2016

Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a C. difficile-infected recipient, and has long been a successful approach to recurrent/refractory C. difficile. The purpose of this project is to generate a frozen FMT inoculum from well-screened healthy volunteer donors which can be used repeatedly, particularly in those who do not have a healthy intimate partner or other related donor. Delivery of FMT has been performed colonoscopically, by fecal retention enema, or by the nasogastric route. This study will evaluate the safety and secondarily the efficacy of an inoculum administered by frozen orally-administered capsules.

Subjects with recurrent/relapsing C. difficile infection will receive FMT via oral capsules

The primary endpoint is assessment of safety as measured by clinical events (GI, procedural, systemic). Efficacy will be defined as a resolution of diarrhea off antibiotics for C. difficile, in the absence of a need for OTHER systemic antibiotics, i.e. resumption of a normal bowel status for the individual. Secondary efficacy endpoints include weight, subjective well-being and relative clinical improvement per standardized questionnaire, and subject qualitative assessment of, and satisfaction with, the transplant procedures. Subjects will be monitored for clinical safety by history and standard exams and the follow-up questionnaire as well as followed closely by phone and in person.

Condition Intervention Phase
Clostridium Difficile Infection Drug: Fecal Microbiota Transplant Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fecal Microbiota Transplant (FMT) for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum

Resource links provided by NLM:

Further study details as provided by Elizabeth L. Hohmann, MD, Massachusetts General Hospital:

Primary Outcome Measures:
  • Safety [ Time Frame: Up to 6 months post-FMT ]
    Safety is assessed by clinical symptoms, exam, signs (GI and systemic)

Secondary Outcome Measures:
  • Efficacy [ Time Frame: Up to 2 months post-FMT ]
    Efficacy is defined as resolution of C. Difficile signs and symptoms off antibiotics for C. difficile

Enrollment: 20
Study Start Date: August 2013
Study Completion Date: October 2014
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Capsule
Fecal microbiota transplant ("stool transplant") from healthy, unrelated donor via frozen capsule
Drug: Fecal Microbiota Transplant
Reconstitution of normal flora by a "stool transplant" from a healthy individual to a C. difficile - infected recipient via frozen capsule
Other Names:
  • Poop transplant
  • Fecal bacteriotherapy


Ages Eligible for Study:   7 Years to 90 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Patients with refractory, recurrent or relapsing C. difficile infection (CDI) defined as EITHER:

    • At least three episodes of mild-to-moderate CDI
    • At least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity
    • One protracted episode of CDI, defined as at least 3 weeks of ongoing Grade 3 severe symptoms of CDI despite standard antimicrobial therapy for CDI
    • We expect that most, but not all, subjects will have tried and failed a taper of vancomycin.
  • Willingness to accept risk of unrelated donor stool
  • Age 7 and above. Seven is chosen as a lower limit based upon the legal age of assent. Based on the literature, most children aged 7 and above can be taught to swallow even large capsules through simple coaching techniques
  • Able to consent for self, or parental assent/child assent as age appropriate

Exclusion criteria

  • Delayed gastric emptying syndrome
  • Known chronic aspiration
  • Swallowing dysfunction or oral-motor dyscoordination.
  • Inability or unwillingness to swallow multiple large capsules
  • Pregnant women
  • Patients with an acute illness unrelated to CDI or an acute exacerbation of underlying comorbid condition
  • Patients with comorbidities associated with increased risk of serious infection following bacterial translocation, including but not limited to:

    • subjects on major immunosuppressive agents including high dose corticosteroids, calcineurin inhibitors, mTOR inhibitors, lymphocyte depleting biologic agents, anti-TNF agents, and others; chemotherapeutic anti-neoplastic agents*
    • Patients with decompensated liver cirrhosis, advanced HIV/AIDS, recent bone marrow transplant, hypoglobulinemia or other cause of severe immunodeficiency*
  • Patients with a history of significant allergy to foods not excluded from the donor diet
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01914731

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Elizabeth Hohmann, MD Massachusetts General Hospital
  More Information

Additional Information:
Responsible Party: Elizabeth L. Hohmann, MD, Principal Investigator, Massachusetts General Hospital Identifier: NCT01914731     History of Changes
Other Study ID Numbers: 2013-P-001355
Study First Received: July 31, 2013
Last Updated: July 15, 2016

Keywords provided by Elizabeth L. Hohmann, MD, Massachusetts General Hospital:
Fecal Microbiota Transplant
Clostridium difficile

Additional relevant MeSH terms:
Communicable Diseases processed this record on August 21, 2017